Developer docs
API playgroundTry for free, no card

Search company profiles

Futurelife

Full company profile

uuid0008ohd

Namestring
Futurelife
Legal namestring
FutureLife
Websiteurl
futurelife.cz
Company typeenum
Private
Founded yearint
1991
Descriptiontext

FutureLife is a Prague-headquartered, privately held pan-European reproductive medicine and genetics group operating 62 fertility clinics across 16 countries with a clinical team of roughly 3,000 specialists. Founded in 1991, the network has facilitated 188,712 births to date (approximately one every 36 minutes) and now conducts over 77,000 IVF cycles annually. The company's core service portfolio spans IUI, IVF, donor programmes, and fertility preservation (egg freezing), supplemented by three specialized sub-brands: GNTlabs by GENNET (an advanced genetic laboratory offering molecular genetics, cytogenetics, preimplantation genetic testing, and bioinformatics), the FutureLife Gamete Bank (a donor egg bank with stringent screening), and Serpha (an online fertility medication pharmacy).

The underlying technology stack combines established clinical IVF laboratory capabilities with a network-wide AI platform deployed in 2026 through a partnership with Alife Health. The platform includes three CE-marked clinical decision support tools — Embryo Predict (blastocyst evaluation), Success Predictor (treatment outcome forecasting), and Egg Retrieval Report (procedure optimization) — making FutureLife the first large-scale European fertility network to institutionalize multi-tool AI across its clinics. Patient access is facilitated through owned clinic locations, a mobile app available on iOS and Android, and the Serpha e-commerce pharmacy.

FutureLife is jointly owned by private equity firms CVC Capital Partners and Hartenberg Holding (the latter owned by Czech billionaire and former Prime Minister Andrej Babiš). The business model is B2C and quote-based per treatment cycle: pricing is not publicly disclosed and varies by treatment type, medication regimen, donor requirements, and clinic location, producing high-touch, multi-year patient journeys with sticky repeat-customer economics. The company has executed a sustained acquisition-led expansion since 2022, absorbing The Centre for Reproductive & Genetic Health, Institut Marquès, BCRM, Bahceci Health Group, and Herts & Essex Fertility Centre across the UK, Spain, and Turkey, positioning the group as a pan-European roll-up platform in a highly fragmented fertility services market.

Short descriptiontext

FutureLife is a Prague-headquartered pan-European fertility and reproductive medicine group operating 62 clinics across 16 countries, providing IVF, IUI, donor programmes, and fertility preservation services to individuals and couples, supplemented by genetic laboratory, gamete bank, and online pharmacy sub-brands.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPrague, Czechia
HQ citystring
Prague
HQ countrystring
Czechia
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fertility treatments, reproductive medicine, IVF services, genetic testing, fertility preservation
Industry2 codes
PRIMARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Family Planning Centers621410
  • Family Planning Centers62141
SIC code1 code
  • Services-Hospitals8060
Product category
Reproductive Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fertility Treatment Services
TypeSubscription Recurring
Description

FutureLife generates revenue through providing fertility treatments including IUI, IVF, donor programmes, and fertility preservation services across their network of 60+ clinics in 16 European countries. Treatment cycles are the primary revenue driver, with over 77,000 IVF cycles conducted annually.

futurelifegroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Individual fertility treatment plans with customized pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed - treatment costs vary based on individual patient needs, treatment type (IUI, IVF, donor programmes, fertility preservation), medication requirements, and specific clinic location.

futurelifegroup.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1GNTlabs by GENNET
Description

One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics.

futurelifegroup.com
+1 more record
Core offering1 text field

FutureLife operates a pan-European fertility and reproductive medicine network of 60+ clinics across 16 countries, providing IUI, IVF, donor programmes, and fertility preservation services. Core offerings are supported by the FutureLife Gamete Bank (donor eggs), GNTlabs by GENNET (genetic testing including PGT, molecular genetics, cytogenetics, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,712 births since 1991.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 188,712 babies delivered since 1991 (one every 36 minutes)
+3 more records
Product overview1 text field

FutureLife is a pan-European fertility and reproductive medicine network offering a comprehensive suite of services across 60+ clinics in 16 countries. The core offerings include IUI, IVF, donor programmes, and fertility preservation (egg freezing). These are supported by the FutureLife Gamete Bank for donor eggs, GNTlabs by GENNET for advanced genetic laboratory services (molecular genetics, cytogenetics, PGT, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,000 births since 1991. A 2026 network-wide AI platform partnership with Alife Health deploys predictive analytics tools (Embryo Predict™, Success Predictor™) and clinical decision support (Egg Retrieval Report) across the clinic network.

Product and service7 records
1Intrauterine Insemination (IUI)
CategoryFertility Treatment Service
Description

Fertility treatment involving placement of sperm directly inside the womb around ovulation time, performed in natural or medicated cycles. A less invasive fertility treatment offered across FutureLife's clinic network.

2In Vitro Fertilization (IVF)
CategoryFertility Treatment Service
Description

Highly effective fertility treatment using fertility hormones to stimulate egg production, followed by egg collection and laboratory combination with sperm to create embryos. The company's primary revenue driver, with over 77,000 IVF cycles conducted annually across the network.

3Donor Programme
CategoryFertility Treatment Service
Description

Treatment pathway utilizing donated eggs or sperm to help individuals and couples create families through assisted reproduction, supported by the FutureLife Gamete Bank donor egg supply.

4Fertility Preservation (Egg Freezing)
CategoryFertility Treatment Service
Description

Oocyte cryopreservation service allowing women to preserve fertility by freezing and storing eggs for future use, suitable for personal, social, or medical reasons including prior to medical treatments that may affect fertility.

5FutureLife Gamete Bank
CategoryDonor Gamete Service
Description

Europe's leading assisted reproductive technology donor egg bank offering thorough donor screening, skilled doctors, and a caring approach to maximize chances of treatment success for patients requiring donor gametes.

6GNTlabs by GENNET
CategoryGenetic Laboratory Services
Description

One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), and bioinformatics, as well as embryology and immunology. Offers genetic screenings, carrier tests, and diagnostic tests for genetic disorders to support fertility treatment decisions.

7Serpha
CategoryPharmacy / Medication Supply
Description

Online pharmacy specializing in fertility medication, supporting patients throughout their fertility treatment journey. Accessible via www.serpha.eu.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-05
Description

FutureLife Group announced a network-wide partnership with Alife Health to deploy a comprehensive AI platform for fertility care across its 60 clinics spanning 16 European countries. The deployment includes Embryo Predict™ (CE-marked AI tool for blastocyst evaluation), Success Predictor™, and Egg Retrieval Report tools, following a successful multi-clinic pilot program. This makes FutureLife the first large-scale European fertility network to adopt a multi-tool AI platform, aiming to standardize reporting, improve clinical consistency, and extend data-driven patient support throughout the IVF journey.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based fertility clinic network offering IVF, IUI, donor, and genetic services across multiple sites. Direct competitor to FutureLife's UK operations (BCRM, Herts & Essex, CRGH) with similar service mix and patient segment.

TypeDirect peer
Description

Spanish fertility clinic network offering IVF, donor programmes, and genetic services with a strong Iberian presence. Directly comparable to FutureLife's Institut Marquès subsidiary and overlapping patient segments.

TypeBroad incumbent
Description

Australia-headquartered fertility and diagnostics network with international operations across multiple countries. Comparable to FutureLife in pan-regional fertility network scale and clinic-based service delivery model.

TypeDirect peer
Description

UK fertility clinic group offering full-service IVF, donor, and genetic testing services. Direct competitor to FutureLife's UK clinics, with overlapping patient demographics and similar clinical offerings.

TypeDirect peer
Description

US fertility clinic network with international expansion ambitions, offering IVF, donor, and genetic services. Comparable to FutureLife in multi-clinic fertility network model and PE-backed growth trajectory.

TypeDirect peer
Description

UK-based fertility network specializing in mild/mild-stim IVF and natural-cycle approaches. Comparable to FutureLife in clinic-network structure and core IVF/IUI offerings, particularly relevant overlap in the UK market.

TypeDirect peer
Description

Sweden-based healthcare services provider with significant fertility clinic operations across Central and Eastern Europe. Comparable to FutureLife in geographic footprint across CEE and similar clinic-based reproductive service model.

8GeneraLife (IVI-RMA)
TypeDirect peer
Description

Europe's largest fertility network operating across Spain, Italy, and other markets with similar IVF, IUI, donor, and genetic services. Closest direct competitor to FutureLife in pan-European fertility clinic scale and PE-backed consolidation model (KKR-backed).

TypeDirect peer
Description

US-based fertility network known for advanced reproductive technology and high success rates, with own genetic lab. Comparable to FutureLife's vertical integration including GNTlabs and strong IVF success-rate positioning.

TypeDirect peer
Description

Part of Fresenius Helios hospital group, Eugin operates fertility clinics across Southern Europe (Spain, Italy, Portugal, Germany). Comparable to FutureLife in clinic-based IVF services and donor programmes, with the added advantage of hospital-system affiliation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Futurelife

Reproductive Medicinefuturelife.cz

FutureLife is a Prague-headquartered pan-European fertility and reproductive medicine group operating 62 clinics across 16 countries, providing IVF, IUI, donor programmes, and fertility preservation services to individuals and couples, supplemented by genetic laboratory, gamete bank, and online pharmacy sub-brands.

What Futurelife does

FutureLife is a Prague-headquartered, privately held pan-European reproductive medicine and genetics group operating 62 fertility clinics across 16 countries with a clinical team of roughly 3,000 specialists. Founded in 1991, the network has facilitated 188,712 births to date (approximately one every 36 minutes) and now conducts over 77,000 IVF cycles annually. The company's core service portfolio spans IUI, IVF, donor programmes, and fertility preservation (egg freezing), supplemented by three specialized sub-brands: GNTlabs by GENNET (an advanced genetic laboratory offering molecular genetics, cytogenetics, preimplantation genetic testing, and bioinformatics), the FutureLife Gamete Bank (a donor egg bank with stringent screening), and Serpha (an online fertility medication pharmacy).

The underlying technology stack combines established clinical IVF laboratory capabilities with a network-wide AI platform deployed in 2026 through a partnership with Alife Health. The platform includes three CE-marked clinical decision support tools — Embryo Predict (blastocyst evaluation), Success Predictor (treatment outcome forecasting), and Egg Retrieval Report (procedure optimization) — making FutureLife the first large-scale European fertility network to institutionalize multi-tool AI across its clinics. Patient access is facilitated through owned clinic locations, a mobile app available on iOS and Android, and the Serpha e-commerce pharmacy.

FutureLife is jointly owned by private equity firms CVC Capital Partners and Hartenberg Holding (the latter owned by Czech billionaire and former Prime Minister Andrej Babiš). The business model is B2C and quote-based per treatment cycle: pricing is not publicly disclosed and varies by treatment type, medication regimen, donor requirements, and clinic location, producing high-touch, multi-year patient journeys with sticky repeat-customer economics. The company has executed a sustained acquisition-led expansion since 2022, absorbing The Centre for Reproductive & Genetic Health, Institut Marquès, BCRM, Bahceci Health Group, and Herts & Essex Fertility Centre across the UK, Spain, and Turkey, positioning the group as a pan-European roll-up platform in a highly fragmented fertility services market.

Futurelife firmographics

Firmographics
Name
Futurelife
Legal name
FutureLife
Website
https://futurelife.cz
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
101–250 employees
Short description
FutureLife is a Prague-headquartered pan-European fertility and reproductive medicine group operating 62 clinics across 16 countries, providing IVF, IUI, donor programmes, and fertility preservation services to individuals and couples, supplemented by genetic laboratory, gamete bank, and online pharmacy sub-brands.
Ownership category
akta.pro rank

Futurelife industry classification

Industry
Product category
Reproductive Medicine
NAICS
Family Planning Centers (621410), Family Planning Centers (62141)
SIC
Services-Hospitals (8060)
akta.pro industry
PRIMARYHLAFAJAD
Fertility, Reproductive Endocrinology & IVF Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Fertility treatments
  • Reproductive medicine
  • IVF services
  • Genetic testing
  • Fertility preservation

Where Futurelife is headquartered

Location

Headquarters

HQ city
Prague
HQ country
Czechia
HQ region
Europe

Offices2 records

Markets served

Futurelife business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Fertility Treatment Services: FutureLife generates revenue through providing fertility treatments including IUI, IVF, donor programmes, and fertility preservation services across their network of 60+ clinics in 16 European countries. Treatment cycles are the primary revenue driver, with over 77,000 IVF cycles conducted annually.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractIndividual fertility treatment plans with customized pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Futurelife product offering

Product offering

Core offering

FutureLife operates a pan-European fertility and reproductive medicine network of 60+ clinics across 16 countries, providing IUI, IVF, donor programmes, and fertility preservation services. Core offerings are supported by the FutureLife Gamete Bank (donor eggs), GNTlabs by GENNET (genetic testing including PGT, molecular genetics, cytogenetics, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,712 births since 1991.

Product overview

FutureLife is a pan-European fertility and reproductive medicine network offering a comprehensive suite of services across 60+ clinics in 16 countries. The core offerings include IUI, IVF, donor programmes, and fertility preservation (egg freezing). These are supported by the FutureLife Gamete Bank for donor eggs, GNTlabs by GENNET for advanced genetic laboratory services (molecular genetics, cytogenetics, PGT, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,000 births since 1991. A 2026 network-wide AI platform partnership with Alife Health deploys predictive analytics tools (Embryo Predict™, Success Predictor™) and clinical decision support (Egg Retrieval Report) across the clinic network.

Differentiator

Problem solved

Functional benefit

Brands

  • GNTlabs by GENNET: One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, PGT, and bioinformatics.
  • Serpha

Products and services

  • Intrauterine Insemination (IUI) Fertility treatment involving placement of sperm directly inside the womb around ovulation time, performed in natural or medicated cycles. A less invasive fertility treatment offered across FutureLife's clinic network.
  • In Vitro Fertilization (IVF) Highly effective fertility treatment using fertility hormones to stimulate egg production, followed by egg collection and laboratory combination with sperm to create embryos. The company's primary revenue driver, with over 77,000 IVF cycles conducted annually across the network.
  • Donor Programme Treatment pathway utilizing donated eggs or sperm to help individuals and couples create families through assisted reproduction, supported by the FutureLife Gamete Bank donor egg supply.
  • Fertility Preservation (Egg Freezing) Oocyte cryopreservation service allowing women to preserve fertility by freezing and storing eggs for future use, suitable for personal, social, or medical reasons including prior to medical treatments that may affect fertility.
  • FutureLife Gamete Bank Europe's leading assisted reproductive technology donor egg bank offering thorough donor screening, skilled doctors, and a caring approach to maximize chances of treatment success for patients requiring donor gametes.
  • GNTlabs by GENNET One of Europe's most advanced genetic laboratories specializing in molecular genetics, cytogenetics, preimplantation genetic testing (PGT), and bioinformatics, as well as embryology and immunology. Offers genetic screenings, carrier tests, and diagnostic tests for genetic disorders to support fertility treatment decisions.
  • Serpha Online pharmacy specializing in fertility medication, supporting patients throughout their fertility treatment journey. Accessible via www.serpha.eu.

Quantifiable outcome

  • 188,712 babies delivered since 1991 (one every 36 minutes)
  • +3 more outcomes

Companies that use Futurelife

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Futurelife technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Futurelife partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alife HealthcoreTechnology or Integration · 5 May 2026FutureLife Group announced a network-wide partnership with Alife Health to deploy a comprehensive AI platform for fertility care across its 60 clinics spanning 16 European countries. The deployment includes Embryo Predict™ (CE-marked AI tool for blastocyst evaluation), Success Predictor™, and Egg Retrieval Report tools, following a successful multi-clinic pilot program. This makes FutureLife the first large-scale European fertility network to adopt a multi-tool AI platform, aiming to standardize reporting, improve clinical consistency, and extend data-driven patient support throughout the IVF journey.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Futurelife competitors and assessment

Company assessment

Direct peers

  • TFP (The Fertility Partnership): UK-based fertility clinic network offering IVF, IUI, donor, and genetic services across multiple sites. Direct competitor to FutureLife's UK operations (BCRM, Herts & Essex, CRGH) with similar service mix and patient segment.
  • Ginemed: Spanish fertility clinic network offering IVF, donor programmes, and genetic services with a strong Iberian presence. Directly comparable to FutureLife's Institut Marquès subsidiary and overlapping patient segments.
  • CARE Fertility: UK fertility clinic group offering full-service IVF, donor, and genetic testing services. Direct competitor to FutureLife's UK clinics, with overlapping patient demographics and similar clinical offerings.
  • Boston IVF: US fertility clinic network with international expansion ambitions, offering IVF, donor, and genetic services. Comparable to FutureLife in multi-clinic fertility network model and PE-backed growth trajectory.
  • CREATE Fertility: UK-based fertility network specializing in mild/mild-stim IVF and natural-cycle approaches. Comparable to FutureLife in clinic-network structure and core IVF/IUI offerings, particularly relevant overlap in the UK market.
  • Medicover: Sweden-based healthcare services provider with significant fertility clinic operations across Central and Eastern Europe. Comparable to FutureLife in geographic footprint across CEE and similar clinic-based reproductive service model.
  • GeneraLife (IVI-RMA): Europe's largest fertility network operating across Spain, Italy, and other markets with similar IVF, IUI, donor, and genetic services. Closest direct competitor to FutureLife in pan-European fertility clinic scale and PE-backed consolidation model (KKR-backed).
  • CCRM (Colorado Center for Reproductive Medicine): US-based fertility network known for advanced reproductive technology and high success rates, with own genetic lab. Comparable to FutureLife's vertical integration including GNTlabs and strong IVF success-rate positioning.
  • Eugin (Fresenius Helios): Part of Fresenius Helios hospital group, Eugin operates fertility clinics across Southern Europe (Spain, Italy, Portugal, Germany). Comparable to FutureLife in clinic-based IVF services and donor programmes, with the added advantage of hospital-system affiliation.

Broad incumbents

  • Virtus Health: Australia-headquartered fertility and diagnostics network with international operations across multiple countries. Comparable to FutureLife in pan-regional fertility network scale and clinic-based service delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Futurelife social profiles

Digital presence

Futurelife financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Futurelife leadership team

Management profile

Number of profiles

Profiles1 record

Futurelife subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Futurelife funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Futurelife M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Futurelife

What does Futurelife do?

FutureLife operates a pan-European fertility and reproductive medicine network of 60+ clinics across 16 countries, providing IUI, IVF, donor programmes, and fertility preservation services. Core offerings are supported by the FutureLife Gamete Bank (donor eggs), GNTlabs by GENNET (genetic testing including PGT, molecular genetics, cytogenetics, bioinformatics), and Serpha online pharmacy for fertility medications. The company conducts over 77,000 IVF cycles annually and has facilitated over 188,712 births since 1991.

Is Futurelife a public or private company?

Futurelife is a private company. It is classified as private equity controlled and is currently operating.

When was Futurelife founded?

Futurelife was founded in 1991. It employs 101 to 250 people.

Where is Futurelife based?

Futurelife is headquartered in Prague, Czechia, in the Europe region.

How does Futurelife make money?

One revenue line is on record: fertility Treatment Services.

Who are Futurelife's main competitors?

Direct peers on record are TFP (The Fertility Partnership), Ginemed, CARE Fertility, Boston IVF, CREATE Fertility, Medicover, GeneraLife (IVI-RMA), CCRM (Colorado Center for Reproductive Medicine) and Eugin (Fresenius Helios). Virtus Health is listed as a broad incumbent.

Does Futurelife have an API?

No public API is recorded for Futurelife.

What industry is Futurelife in?

Futurelife's product category is Reproductive Medicine. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 621410 and its SIC code is 8060.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFutureLife devient le premier réseau européen de fertilité à adopter une plateforme de fertilité optimisée par l'IA, en partenariat avec Alife HealthFutureLife Group, a leading pan-European fertility and IVF services provider, has announced a network-wide partnership with Alife Health to deploy a comprehensive AI platform for fertility care across its clinics in 16 countries, making it the first large-scale European fertility network to adopt a multi-tool AI platform. The deployment includes Embryo Predict™, Alife's CE-marked AI tool for blastocyst evaluation, along with Success Predictor™ and Egg Retrieval Report tools, following a successful multi-clinic pilot program. FutureLife conducts over 77,000 IVF cycles annually across 60 clinics and is jointly owned by private equity firms CVC and Hartenberg.PR NewswireFutureLife becomes first European fertility network to adopt an end-to-end AI fertility platform, in partnership with Alife HealthFutureLife Group announced a network-wide partnership with Alife Health to deploy a comprehensive AI platform for fertility care across its 60 clinics spanning 16 European countries. The platform includes Alife's CE-marked Embryo Predict™ tool for blastocyst assessment and other AI-driven clinical decision support tools, making FutureLife the first large-scale European fertility network to make an institutional commitment to a multi-tool AI platform. The collaboration follows a successful multi-clinic pilot and aims to standardize reporting, improve clinical consistency, and extend data-driven patient support throughout the IVF journey.POLITICOIVF, lingerie and funeral flowers: The lesser-known businesses of Czech PM Andrej BabišCzech Prime Minister Andrej Babiš faces renewed scrutiny over potential conflicts of interest as the European Commission has asked Czech authorities to explain how conflicts of interest are being prevented across all companies linked to him, beyond the already-examined Agrofert, while simultaneously halting some agricultural subsidies to Agrofert pending a fresh legal review. Babiš's business empire includes Hartenberg Holding, a private-equity vehicle with roughly €600 million in assets spanning IVF clinic network FutureLife (60 clinics across 16 countries), online lingerie retailer Astratex, and florist chain Flamengo — all operating in sectors shaped by public spending and regulation, yet not covered by his trust arrangements. EU auditors and lawmakers say the fragmented beneficial ownership registers across member states make it difficult or impossible to determine which of Babiš's companies receive EU funds, raising concerns about his role negotiating the bloc's long-term budget and agricultural subsidies from the European Council.Expats.czCzech billionaires expand UK footprint with major business acquisitionsTwo Czech companies owned by billionaires are expanding into the UK through separate acquisitions: Sev.en Global Investments, owned by Pavel Tykač, has acquired Celsa Steel UK's steel plant in Cardiff, Wales, with annual production capacity of 1.2 million tons of low-emission construction steel, marking Sev.en GI's continued diversification beyond energy and mining. Meanwhile, former Czech Prime Minister Andrej Babiš's FutureLife healthcare company announced plans to acquire and open a large network of assisted reproduction clinics in the UK, building on its existing dominance of over a third of the Czech market. Both companies are leveraging these acquisitions to strengthen their international footprint and expand into new sectors.FuturelifegroupInstitut MarquesFutureLife has announced the acquisition of Institut Marquès, a leading IVF provider with clinics in Spain and Italy, to expand its Pan-European presence. Backed by Hartenberg Holding and CVC Capital Partners, FutureLife aims to leverage this partnership to scale innovative fertility treatments and patient-centric approaches across the region.